Blue Owl Capital Holdings’s Keros Therapeutics KROS Stock Holding History

Blue Owl Capital Holdings’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-266,033	Closed	-$2.71M	–	76
2025 Q1	$2.71M	Buy	266,033 +23,400	+10%	+$272K	0.87%	28
2024 Q4	$3.84M	Buy	242,633 +120,000	+98%	+$6.24M	0.89%	25
2024 Q3	$7.12M	Sell	122,633 -35,000	-22%	-$1.73M	1.37%	19
2024 Q2	$7.2M	Sell	157,633 -15,000	-9%	-$806K	2%	16
2024 Q1	$11.4M	Sell	172,633 -180,000	-51%	-$10.7M	2.28%	13
2023 Q4	$14M	Buy	+352,633	New	+$11.1M	3.35%	10

Other funds holding KROS

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Blue Owl Capital Holdings's KROS Position: Q2 2025 in Review

Blue Owl Capital Holdings sold out of Keros Therapeutics (KROS) in Q2 2025, closing a stake of 266,033 shares — an estimated $2.71M sold.

Blue Owl Capital Holdings first reported a position in KROS in Q4 2023 and held it in 6 quarters. The position peaked at $14M in Q4 2023. 139 funds tracked by Wall St. Rank hold KROS as of Q2 2025.

Blue Owl Capital Holdings reported no remaining Keros Therapeutics position as of Q2 2025 after selling out during the quarter.
Blue Owl Capital Holdings sold 266,033 Keros Therapeutics shares in Q2 2025, an estimated $2.71M.
Blue Owl Capital Holdings first reported a position in Keros Therapeutics in Q4 2023 and held it in 6 quarters.
Blue Owl Capital Holdings's Keros Therapeutics position peaked at $14M in Q4 2023.
139 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2025.

Based on Blue Owl Capital Holdings's 13F filing for Q2 2025, filed 11 Aug 2025.